Abstract: An object of the disclosure is to provide a composition for evaluating the hepatic glucose uptake capacity of a subject and a method for evaluating the hepatic glucose uptake capacity of a subject with the composition. An object of the disclosure is to provide a method for determining the stage of pre-onset diabetes in a subject with pre-onset diabetes using the method for evaluating the hepatic glucose uptake capacity. An aspect of the disclosure accordingly provides a composition comprising 13C-labeled glucose for evaluating the hepatic glucose uptake capacity of a subject. Another aspect of the disclosure provides a method comprising measuring 13C-labeled glucose in a blood sample or an expired air sample obtained from the subject to which the composition was administered. The desired evaluation or determination can be achieved by comparing the measured value with a reference value.
Type:
Application
Filed:
November 10, 2017
Publication date:
October 24, 2019
Applicants:
OTSUKA PHARMACEUTICAL CO., LTD., TOHOKU UNIVERSITY
Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.
Abstract: The present invention relates to a prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease, which contains 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient.
Type:
Application
Filed:
June 28, 2019
Publication date:
October 17, 2019
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Shinji SATO, Kenji MAEDA, Dai ISHIKAWA, Mai NAKAMURA
Abstract: The present invention provides a composition for suppressing muscular atrophy, comprising as an active ingredient(s) one or more peptides selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; the group consisting of dipeptides comprising F; and the group consisting of dipeptides DI, IY, YN, and NP.
Abstract: This invention provides a method for measuring insulin resistance of a test subject, and a composition suitably used for the method. A method for measuring insulin resistance of a test act comprising steps (a) and (b) below, the method using a composition for measuring insulin resistance comprising, as an active ingredient, a C12-38 fatty acid labeled with at least one isotope of C, wherein the C12-38 fatty acid is converted in the body into labeled carbon dioxide that is excreted in expired air, (a) intravenously administering the composition to a test subject and collecting expired air; and (b) determining the ratio of labeled CO2 amount to unlabeled CO2 amount contained in the expired air or the ratio of labeled CO2 amount to total CO2 amount contained in the expired air.
Abstract: Iohexol particles, contrast agent compositions comprising iohexol particles, methods of preparing iohexol particles, and methods of administering iohexol particles are provided herein. The iohexol particles of the present invention substantially dissolve in water within about 60 seconds when tested using Modified United States Pharmacopeia Method 641.
Type:
Application
Filed:
June 5, 2019
Publication date:
October 3, 2019
Applicant:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Jirí PROKOP, Ivan HLAVÁCEK, Petr ZAHRADNÍK, Jirí MALINAK
Abstract: The present invention relates to a single-chain circular RNA having a sustained or slow-releasing RNA interference effect, characterized in that the single-chain circular RNA comprises a sense strand sequence, an antisense strand sequence complementary to the sense strand sequence, identical or different two loop sequences between the sense strand and the antisense strand, connecting both strands, wherein the sense strand and the antisense strand are paired to form a stem.
Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.
Type:
Application
Filed:
June 9, 2017
Publication date:
September 12, 2019
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Thomas Daniel HEIGHTMAN, Honorine LEBRAUD
Abstract: A risk management system (RMS) device includes a RMS database and a RMS processor. The RMS processor includes a prescriber module to receive a request to enroll a patient in a RMS program of a therapeutic agent associated with multiple indications. The request includes a specification of at least one indication, and a confirmation of a diagnostic test conducted on the patient. The RMS processor also includes a patient module configured to generate a patient profile. The RMS processor also includes a database module configured to store the patient profile in the RMS database. The RMS processor also includes an authorization module configured to generate an authorization code indicating whether the patient is authorized to receive the therapeutic agent. The RMS processor also includes a communication module configured to transmit the authorization code to a pharmacy or a prescriber.
Type:
Grant
Filed:
July 26, 2016
Date of Patent:
September 10, 2019
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Frank S. Czerwiec, Amy Freedman, Keith Friend, Elaine A. O'Hara, Craig Ostroff, Marcelo De Freitas Santoro, Charles Shiner, Takeshi Watanabe, Miho Yamamoto, Christopher A. Zimmer
Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.
Abstract: A method for measuring energy malnutrition in a liver disease test subject, a method for determining whether a liver disease test subject is in an energy malnutrition state, a method for determining the necessity of nutrition therapy for a liver disease test subject having energy malnutrition, a composition usable in these methods, and the like are provided. The method for measuring energy malnutrition in a liver disease test subject includes the steps of collecting expired air containing labeled carbon dioxide that is generated in the body of a liver disease test subject by being converted from a composition containing, as an active ingredient, glucose labeled with at least one isotope C; and determining the ratio of labeled CO2 amount to unlabeled CO2 amount, or the ratio of labeled CO2 amount to total CO2 amount in expired air.
Abstract: An object of the invention is to provide a method for assisting diagnosis of Alzheimer's disease (AD), and a detection reagent, a diagnosis kit and a diagnosis system for use in the method. Provided is a method for assisting diagnosis of AD, comprising the steps of: measuring an amount of a urine biomarker in a urine sample derived from urine collected from a subject; and determining whether the subject suffers from AD or has a high risk of developing AD based on the amount of the urine biomarker measured, wherein the urine biomarker is at least one urine protein selected from the group consisting of ApoA-I, ApoA-II, ApoA-IV, ApoB-100, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, IFITM1, IFITM2, IFITM3, NPC1, NPC2, NPC1L1, and MT.
Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
Abstract: [Object] An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. [Method for Achieving the Object] A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).
Abstract: A container (1) includes: a first storage section (11) for storing a plurality of solid objects (200); a second storage section (12) provided so as to be capable of being in communication with the first storage section (11) through a predetermined communication opening (50) and also so as to be capable of being in communication with an outside space (300) through a predetermined extraction opening (100); a tray (20) having a receiving section (80) which receives one solid object (200) supplied from the first storage section (11) to the second storage section (12), the tray (20) also having a first wall section (91) capable of closing the communication opening (50), the tray (20) further having a second wall section (92) capable of closing the extraction opening (100), the tray (20) being stored in the second storage section (12); and a movement mechanism (17) for sliding the tray (20) within the second storage section (12) between a first position at which the communication opening (50) is open and the extrac
Abstract: Iohexol particles, contrast agent compositions comprising iohexol particles, methods of preparing iohexol particles, and methods of administering iohexol particles are provided herein. The iohexol particles of the present invention substantially dissolve in water within about 60 seconds when tested using Modified United States Pharmacopeia Method 641.
Type:
Grant
Filed:
March 4, 2015
Date of Patent:
July 16, 2019
Assignee:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Ji{hacek over (r)}í Prokop, Ivan Hlavá{hacek over (c)}ek, Petr Zahradník, Ji{hacek over (r)}í Malinak
Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
Type:
Application
Filed:
May 26, 2017
Publication date:
July 4, 2019
Applicants:
AMINO UP CHEMICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
Abstract: In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the group consisting of copper iodide, copper chloride, copper bromide, copper sulfate, copper formate, or combinations thereof.
Type:
Application
Filed:
October 25, 2018
Publication date:
June 6, 2019
Applicant:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Mark ZDEBLICK, Markus CHRISTEN, Nikhil PARGAONKAR, Nikolaus LEIST, Kurt SCHEINPFLUG, Patricia JOHNSON, Benedict COSTELLO
Abstract: Provided is a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate, which has a broader treatment spectrum, causes less side effects, and is superior in tolerability and safety, and use thereof. A heterocyclic compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.